Imugene Stock Forecast for 2023 - 2025 - 2030
Updated on 03/28/2024
Imugene Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Imugene were recently set by distinguished experts, with an average mark of $0.42. If it reached this goal, it would represent a potential upside of approximately 281.82% from the previous closing price in March, 2024. The high end is $0.49, and the low is $0.10. If you are interested in IMU stock, it is important to also consider its competitors.
281.82% Upside
Imugene Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Imugene's Price has grown by 100.00%, rising from $-0.00 to $0.00. For the next year, analysts predict that Fair Value will reach $0.11 – an increase of 100.00%. Over the next seven years, experts believe that Imugene's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
CSL Stock Forecast | CSL | Outperform |
12
|
$281.20 | Buy/Sell | $205.51 | -27.94% |
TLX Stock Forecast | Telix Pharmaceuticals | Buy |
6
|
$11.29 | Buy/Sell | $13.37 | 24.00% |
NEU Stock Forecast | Neuren Pharmaceuticals | Buy |
11
|
$20.07 | Buy/Sell | $26.43 | 32.44% |
PNV Stock Forecast | PolyNovo | Outperform |
8
|
$2.40 | Buy/Sell | $1.88 | -10.83% |
CUV Stock Forecast | Clinuvel Pharmaceuticals | Buy |
16
|
$13.21 | Buy/Sell | $27.41 | 67.68% |
Imugene Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Imugene's Revenue has grown by 185.23%, rising from $4.13M to $11.78M. According to 2 analysts, Imugene's Revenue will fall by 100.00% in the next year, reaching $0.00. Over the next eight years, experts believe that Imugene's Revenue will grow at a rate of 10278.10%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
IMM Stock Forecast | Immutep | Buy |
8
|
$0.40 | Buy/Sell | $1.26 | 137.50% |
MSB Stock Forecast | Mesoblast | Buy |
9
|
$0.32 | Buy/Sell | $0.69 | 100.00% |
PYC Stock Forecast | PYC Therapeutics | Buy |
8
|
$0.08 | Buy/Sell | $0.30 | 337.50% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BOT Stock Forecast | Botanix Pharmaceuticals | - |
0
|
$0.19 | Buy/Sell | $0.00 | -100.00% |
CGS Stock Forecast | Cogstate | Outperform |
11
|
$1.22 | Buy/Sell | $1.85 | 39.34% |
DXB Stock Forecast | Dimerix | - |
0
|
$0.30 | Buy/Sell | $0.00 | -100.00% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ACW Stock Forecast | Actinogen Medical |
5
|
$0.03 | Buy/Sell | $0.15 | -100.00% | |
BIT Stock Forecast | Biotron | - |
0
|
$0.07 | Buy/Sell | $0.00 | -100.00% |
SPL Stock Forecast | Starpharma Holdings | - |
8
|
$0.13 | Buy/Sell | $0.95 | -100.00% |
Imugene EBITDA Forecast for 2023 - 2025 - 2030
Imugene's EBITDA has seen growth In the last three years, going from $-10.72M to $-37.26M – a gain of 247.57% In the next year, analysts believe that EBITDA will reach $-62.16M – an increase of 66.83%. For the next seven years, the forecast is forEBITDA to grow by 65.66%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
IVX Stock Forecast | Invion | - |
0
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
PTX Stock Forecast | Prescient Therapeutics | - |
2
|
$0.05 | Buy/Sell | $0.20 | -100.00% |
CYP Stock Forecast | Cynata Therapeutics |
0
|
$0.19 | Buy/Sell | $1.24 | 552.63% |
Imugene EBIT Forecast for 2023 - 2025 - 2030
In the last three years, EBIT for Imugene has grown by 267.63%, going from $-10.75M to $-39.52M. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach $-57.28M – an increase of 44.94%. According to professionals, by 2030, Imugene's EBIT will have decreased by 2975.15%, falling down to $1.14B.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
1AI Stock Forecast | Algorae Pharmaceuticals | - |
-4
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
IMC Stock Forecast | Immuron | - |
0
|
$0.07 | Buy/Sell | $0.00 | -100.00% |
ATH Stock Forecast | Alterity Therapeutics | - |
0
|
$0.00 | Buy/Sell | $0.75 | 0.00% |
Imugene EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Imugene's EPS has grown by 100.00%, rising from $-0.00 to $0.00. For the next year, analysts predict that EPS will reach $-0.01 – an increase of 100.00%. Over the next seven years, experts believe that Imugene's EPS will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
OSL Stock Forecast | OncoSil Medical | - |
0
|
$0.01 | Buy/Sell | $0.11 | -100.00% |
GTG Stock Forecast | Genetic Technologies |
0
|
$0.15 | Buy/Sell | $1.00 | 566.67% | |
BNOX Stock Forecast | Bionomics | Outperform |
-13
|
$1.13 | Buy/Sell | $18.04 | 1279.65% |